Journals / Medical Network Klinik Bilimler ve Doktor / 2005 / Cilt: 11 - Sayı: 3

Comparison of rabeprazole and ranitidine bismuth citrate with triple combination of amoxycilline, clarithromycin and metronidasole in the eradication of Helicobacter pylori

Helikobakter pylori eradikasyonunda rabeprazol ve ranitidin bizmut sitratın amoksisilin, klaritromisin ve metronidazolle oluşturulmuş üçlü kombinasyonlarının karşılaştırılması

Pages
245–249
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

As for as there a drog ressistance agains metronidazole in our country, combinations incluary RBS could be recommended in H.pylori eradication therapies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Objective: Antibiotic resistance strongly affects the success rate of eradication therapy.
📊
Key Findings & Data:In the literature, there are some articles concerning about the prevention of antibiotic resistance by the use of ranitidine bismuth citrate in the eradication regimens.
💡
Conclusion & Impact:As for as there a drog ressistance agains metronidazole in our country, combinations incluary RBS could be recommended in H.pylori eradication therapies.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:İlaç kombinasyonları · İlaç direnci · Metronidazol

Abstract

Objective: Objective: Antibiotic resistance strongly affects the success rate of eradication therapy. In the literature, there are some articles concerning about the prevention of antibiotic resistance by the use of ranitidine bismuth citrate in the eradication regimens. Thus, aim of this study is to observe whether the treatment regimens including ranitidine bismuth citrate could affect the success rate of the eradication of Helicobacter pylori or not when compared with the regimens including proton pompa inhibitors. Material and Method: Patients from outpatient clinic who had gastritis and/or ulcer, diagnosed by upper gastrointestinal endoscopic examination and had the histopathologic evidence of H.pylori were involved into the study. Patients were divided into 4 groups; Group A (n=10) received rabeprazol 2x20 mg, claritromicin 2x500 mg, amoxicillin 2x1000 mg, Group B (n=9) received rabeprazol 2x20 mg, metronidazole 2x500 mg, amoxicillin 2x1000 mg, Group C (n=14) received ranitidine bismuth citrate (RBS) 2x400 mg, claritromicin 2x500 mg, amoxicillin 2x1000 mg and Group D (n=19) ranitidine bismuth citrate (RBS) 2x400 mg, metronidazole 2x500 mg, amoxicillin 2x1000 mg for 14 days. 15 days after the treatment, breath-urea-test was performed to each patient. Results: Total of patient 52 patients (32 female, 20 male) with mean age 46.75±14.11 years, were involved. The number of patient in groups A, B, C,D were 10, 9, 14 and 19, respectively. According to the urea-breath tests, the H. pylori eradication success rate was not found to be statistically significant in between 4 groups. However, when he results of group B and group D were compared, the eradication rate was found to be higher in group B than in group D, but still statistically not significant. (89.5% vs 66.7%, p> 0.05) Conclusion: Although there's no statistically significancy in between the success rate of H.pylori eradication regimens with either RBS or metronidazole, the rate still seems higher with the treatment combinations including rabeprazol than the ones including metronidazole. As for as there a drog ressistance agains metronidazole in our country, combinations incluary RBS could be recommended in H.pylori eradication therapies.

Özet

Amaç: Helikobakter pylori (H.pylori) eradikasyonu için kullanılan antibiyotiklere karşı gelişen direnç eradikasyon başarısını etkiler. Ranitidin bizmut sitratın (RBS) antibiyotik direncini önlediği belirtilmektedir. Çalışmanın amacı RBS'lı rejimlerin proton pompa inhibitörleri içeren rejimlere göre Helikobakter pylori eradikasyonunu etkileyip etkilemediğini araştırmaktır. Gereç ve Yöntem: Çalışma kapsamına; dispeptik yakınmaları sebebiyle polikliniğimize başvurmuş, üst gastrointestinal sistem endoskopisinde gastrit ve/veya ülser tespit edilen, histopatolojik olarak H. pylori varlığı kanıtlanmış hastalar dahil edilmiştir. Hastalar 4 gruba ayrılmış, Grup A'ya rabeprazol 2x20 mg, klaritromisin 2x500 mg, amoksisilin 2x1000 mg, grup B'ye rabeprazol 2x20 mg, metronidazol 2x500 mg, amoksisilin 2x1000 mg, grup C'ye RBS 2x400 mg, klaritromisin 2x500 mg, amoksisilin 2x1000 mg. ve grup D'ye hastaya RBS 2x400 mg, metronidazol 2x500 mg, amoksisilin 2x1000 mg, 14 gün tedavisi uygulanmıştır. Tedavi bitiminde 15 gün PPI veya RBS kullanmayan hastalara üre soluk testi uygulanılmıştır. Bulgular: Çalışmaya yaş ortalaması 46.75±14.11 yıl olan, 32'si kadın toplam 52 hasta alınmıştır. Gruplara göre hasta sayısı sırasıyla 10, 9, 14 ve 19'dur. Gruplar birbiriyle karşılaştırıldığında hiçbir grup arasında eradikasyon başarısı oranında istatistiki bir fark saptanmamıştır.(p>0.05) Metronidazol içeren RBS'lı grup (D grubu) ile rabeprazol'lü grup (B grubu) karşılaştırıldığında istatistiksel fark olmamasına rağmen RBS'li grupta (%89.5) eradikasyon oranı, rabeprzollü gruptan (%66.7) yüksek bulunmuştur. Sonuç: RBS ve metronidazol içeren kombinasyon grubunda eradikasyon oranı rabeprazol ve metronidazol içeren gruba göre istatistiksel olarak anlamlı olmasa da daha yüksektir. Ülkemizde metronidazol direnci yüksek olduğundan metronidazol ile uygulanacak Hp. Eradikasyonunda RBS'lı kombinasyonların tercih edilmesi önerilebilir.

🔖

Cite This Article

SÖKMEN, H. M., DEMİRSOY, H., KARACA, Ç., KESİCİ, B., ÖZDİL, K., ERSOY, Ö., AKBAYIR, N., ALKIM, C., ERDEM, L., SAKIZ, D. (2005). Comparison of rabeprazole and ranitidine bismuth citrate with triple combination of amoxycilline, clarithromycin and metronidasole in the eradication of Helicobacter pylori. Medical Network Klinik Bilimler ve Doktor, Cilt: 11 - Sayı: 3, 245–249. https://ajindex.com/articles/278361

References (16)

  1. McQaid KR. Dyspepsia. In Feldman M, Friedman LS, Sleisenger MH. Editors. Gastrointestinal and Liver Disease. 7 th ed. Saunder 2002:102-18
  2. Dunn BE, Cohen H, Blaser MJ. Helicobacter Pylori. Clinical Microbiology Reviews 1997; 10:720-41
  3. Shiotani A, Nurgalivea ZZ, Yamaoka Y, et al. Helicobacter pylori. Med Clin North Am 2000; 84:1125-36
  4. Peterson WL. Helicobacter pylori and peptic ulcer disease. N EnglJ Med 1991; 324:1043-8
  5. Alarcon T, Domingo D, Lopez-Brea M. Antibiotic resistance problems with Helicobacter pylori Review article, internal Journal of Antimicrobial Agents 12 1909:19-26
  6. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in peptic ulcer disease. J Am Med Assoc 1994; 272:65-9
  7. Malfertheiner P, Megraud F, O'Morain C, et al. The European Helicobacter. pylori study group (EHPSG). Current concepts in the management of Helicobacter.pylori infection The Maastricht 2-2000 Consensus report. Aliment Pharmacol Ther 2002; 16:167-80
  8. Beşışık F. Türkiye'de Helicobacter pylori sorunu. Göksoy E. Ed. Aktüel Gastroenteroloji ve Hepatoloji-I, 2. Edisyon, Bilmedya grup, İstanbul 2003:39-50
  9. Glupczynski Y, Megraud F, Lopez-Brea M. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbial Infect Dis 2001; 20:820-3
  10. Bağlan HP, Özden A. Helicobacter pylori'nin antibiyotiklere direnci. Güncel Gastroenteroloji 2003; 7:220-5
  11. Lind T, Veldhuyzen van Zanten SJO, Unge P, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antibiotics: the MACH1 study. Helicobacter 1996; 1:138-44
  12. Veldhuyzen Van Zanten SJO, Bradette M, Farley A, et al. The DUMACH study: eradication of Helicobacter pylori and ulcer nealing in patients with acute duodenal ulcer using omeprazole Dased triple therapy. Aliment Pharmacol Ther 1999; 13:289-95
  13. The European Helicobacter pylori Study Group. Current European concepts in the management of Helicobacter pylori ifection. The Maastricht Consensus Report. Gut 1997; 41:8-13
  14. Özden A. Helikobakter pylori enfeksiyonu tedavisinde bizmut uzlarının yeri. Özden A, Ed. Mikrop ve Mide Hastalıkları, Türk 3astroenteroloji vakfı. 1.basım, Ankara 2004:208-20
  15. Glupczynski Y. Antimicrobial rezistance in Helicobacter pylori: a global overview. Acta Gastroenterol Belg 1998; 61:357-66
  16. Özden A. Helicobacter pylori tedavisinde kullanılan ilaçla